Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine, ...
Please provide your email address to receive an email when new articles are posted on . Of adults who did not lose 5% of their weight with tirzepatide at 12 weeks, 90% achieved 5% weight loss at 72 ...
In the context of the global obesity epidemic, the FDA approved several glucagon-like peptide-1 (GLP-1) receptor agonists (GPL-1RAs), such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy) as ...
Study reveals that GLP-1 therapy increases visceral adipose tissue metabolism, significantly contributing to weight loss in individuals with obstructive sleep apnea. Study: GLP-1 therapy increases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results